

RECEIVED

MAR 17 2003

TECH CENTER 1600/2800

Attorney Docket No. A33865-090495.0233
PATENT

REMARKS

This paper is being filed in response to the Office Communication dated March 11, 2003. Applicants respectfully request reconsideration of the above-identified application in light of the amendments and remarks presented herein.

Claims 44-48, 54, 65-69, 121 and 133 are pending. Claim 66 has been amended to correct inadvertent typographical errors. No new matter has been introduced by the amendment to claim 66. Support for the amendment can be found in original claim 66.

In accordance with 37 C.F.R. § 1.121, Applicant has provided (1) accurate instructions to amend the claims, (2) replacement claims in clean form herein, and (3) another version of the amended claims marked up to show all the changes relative to the previous version, which appears on an attached page.


In the Office Communication, The Examiner indicates that the response was incomplete because Applicants failed to elect a specific chemotactic factor, as was required in Section 6 of the Restriction Requirement. As noted by the Examiner, this was an oversight by Applicants. Accordingly Applicants wish to elect MIP-3 β as the specific chemotactic factor. The Examiner further indicated in the Office Communication that upon the election of species, the Examiner would rejoin Group IX and X and that claims 44-48, 65-69 and 121 and 133 will be examined. Applicants wish to point out that claim 54 should also be included because it was included in Group X.

BAKER BOTTS L.L.P.

Attorney Docket No. A33865-090495.0233
PATENT

Applicants do not believe that any fee is required in connection with this submission. Nevertheless, the Commissioner is hereby authorized to charge any fees required for this submission to Deposit Account No. 02-4377. Two copies of this page are enclosed.

Respectfully submitted,



Rochelle K. Seide
Patent Office Reg. No. 32,300

Alicia A. Russo
Patent Office Reg. No. 46,192

30 Rockefeller Plaza
New York, NY 10112-4498
Attorneys for Applicants
(212) 408-2627

VERSION WITH MARKINGS TO SHOW CHANGES MADE

Please rewrite claim 66 as follows:

66. (Twice Amended) The method of claim 46, 47, 48 or 133 wherein the chemokine is selected from the group consisting of MIP-1[γ] α , RANTES, MCP-3, MIP-5, MCPs, TARC, MDC, MIP-3[γ] α , IL-8, SDF-1, MIP-3[γ] β and SLC.